Tirzepatide results in 'a couple months': what the data actually shows
Quick answer
The creator reports visible body composition changes after a few months on tirzepatide, consistent with early-phase outcomes documented in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM). However, the #hormonehealth framing in her hashtags implies a hormonal mechanism that goes beyond tirzepatide's approved indications as a GLP-1/GIP receptor agonist for weight management and type 2 diabetes. Any hormonal benefits, such as improved insulin sensitivity, are secondary to weight loss rather than a direct drug effect.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @abitboujie actually say?
Honestly, not much, at least not factually. The entire transcript is "I'm in love, I'm obsessed, and I don't even feel guilty about it." That's an emotional reaction to visible results, not a medical claim. She's describing her experience on tirzepatide over "a couple months" and showing what she calls a body transformation, but she doesn't make specific weight loss claims, promise outcomes for others, or cite any science. She's just happy about her results.
The hashtags do a bit more work here. Tags like #hormoneimbalance and #hormonehealth imply a connection between tirzepatide and hormonal issues, which is worth examining since that framing can mislead viewers into thinking tirzepatide is primarily a hormone therapy rather than a GLP-1/GIP receptor agonist used for weight management and type 2 diabetes.
Does the science back this up?
Visible body composition changes in two to three months on tirzepatide? Yes, that tracks with the data. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed participants on the highest tirzepatide dose (15mg) lost an average of 20.9% of body weight over 72 weeks, with meaningful changes appearing well before that endpoint. Early responders often see noticeable results within the first 12 weeks.
The emotional response she describes, feeling "obsessed" and guilt-free, also mirrors patient-reported outcomes in GLP-1 research. Studies suggest these medications reduce what researchers call "food noise," the persistent mental preoccupation with eating. A 2023 analysis by Rubino et al. in Obesity found significant improvements in quality of life and psychological relationship with food among tirzepatide users. So her emotional framing, while anecdotal, isn't disconnected from what clinical data shows.
What did they get wrong (or right)?
She didn't get anything factually wrong because she didn't make factual claims. That's worth noting. Too many weight loss creators on TikTok make specific promises, cite bogus mechanisms, or imply their results are typical. She did none of that. Credit where it's due.
What's potentially misleading is the packaging, not the words. The hashtags #hormoneimbalance and #hormonehealth suggest tirzepatide addresses hormonal dysfunction directly, and that framing is a stretch. Tirzepatide acts on GLP-1 and GIP receptors to regulate appetite and blood sugar. It can indirectly affect hormonal markers, including improvements in insulin sensitivity and, in some women, menstrual regularity tied to weight loss, but calling it a hormone health intervention is imprecise at best.
- Tirzepatide is FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound).
- It is not approved as a hormone therapy.
- Any hormonal benefits are secondary effects of weight loss, not primary drug mechanisms.
What should you actually know?
If you're a woman over 50 considering tirzepatide, the research is genuinely encouraging but comes with real caveats. The SURMOUNT-1 data is mostly from adults with obesity or overweight plus a weight-related condition. Results vary significantly based on dose, adherence, diet, and individual metabolic factors. Not everyone has a dramatic two-month transformation.
Side effects matter too. Nausea, vomiting, and gastrointestinal discomfort are common, especially during dose escalation. The SURMOUNT trials reported GI adverse events in roughly 40-50% of participants. There are also open questions about muscle mass loss during rapid weight reduction. A 2022 paper by Wilding et al. in Diabetes Care flagged lean mass loss as a concern with GLP-1 class drugs, suggesting resistance training is advisable alongside treatment.
One more thing: "a couple months" is early in the tirzepatide timeline. Long-term maintenance requires continued use. Wilding et al. (2022, Diabetes Care) showed substantial weight regain after stopping semaglutide, a related GLP-1 drug. Tirzepatide is likely similar. The glow-up is real, but it requires ongoing commitment, not a short-term fix.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Tirzepatide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Tirzepatide results in 'a couple months': what the data actually shows, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Compounded Tirzepatide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Claim path
Keep researching this tirzepatide video claims cluster
Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.
Claim verdict
The useful answer behind this video
Claim being checked
The creator reports visible body composition changes after a few months on tirzepatide, consistent with early-phase outcomes documented in the SURMOUNT-1 trial (Jastreboff et al.
FormBlends verdict
The creator reports visible body composition changes after a few months on tirzepatide, consistent with early-phase outcomes documented in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM). However, the #hormonehealth framing in her hashtags implies a hormonal mechanism that goes beyond tirzepatide's approved indications as a GLP-1/GIP receptor agonist for weight management and type 2 diabetes. Any hormonal benefits, such as improved insulin sensitivity, are secondary to weight loss rather than a direct drug effect.
Patient-safe next step
Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator reports visible body composition changes after a few months on tirzepatide, consistent with early-phase outcomes documented in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM). However, the #hormonehealth framing in her hashtags implies a hormonal mechanism that goes beyond tirzepatide's approved indications as a GLP-1/GIP receptor agonist for weight management and type 2 diabetes. Any hormonal benefits, such as improved insulin sensitivity, are secondary to weight loss rather than a direct drug effect.
- SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed average weight loss of 20.9% on 15mg tirzepatide over 72 weeks, with noticeable changes often appearing within the first 12 weeks.
- Tirzepatide is FDA-approved for chronic weight management (Zepbound) and type 2 diabetes (Mounjaro), not for hormone imbalance or hormone health specifically.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.
Review Compounded TirzepatideWhat You'll Learn
- SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed average weight loss of 20.9% on 15mg tirzepatide over 72 weeks, with noticeable changes often appearing within the first 12 weeks.
- Tirzepatide is FDA-approved for chronic weight management (Zepbound) and type 2 diabetes (Mounjaro), not for hormone imbalance or hormone health specifically.
- 40-50% of SURMOUNT trial participants reported gastrointestinal side effects including nausea and vomiting, most commonly during dose escalation.
- Lean muscle mass loss during rapid weight reduction is a documented concern with GLP-1 class drugs (Wilding et al., 2022, Diabetes Care); resistance training is widely recommended alongside treatment.
- Stopping tirzepatide typically leads to weight regain. Evidence from the related semaglutide STEP 1 Extension trial (Wilding et al., 2022) showed participants regained two-thirds of lost weight within one year of stopping treatment.
- The #hormonehealth framing common in weight loss content on social media can blur the line between an anti-obesity medication and hormone therapy, which are distinct treatment categories with different regulatory and clinical profiles.
- Individual results on tirzepatide vary substantially based on dose, adherence, baseline metabolic health, and lifestyle factors. Two-month transformation posts are not a reliable benchmark for expected outcomes.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
🫧Atomic Blond-Susan🫧 · TikTok creator
2.1K views on this video
Check out my results on Tirzepatide in just a couple months. Im literally obsessed with how my bidy has changed. #healthjourney #hormoneimbalance #hormonehealth #womenover50 #glp #tirzepatide
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by 🫧Atomic Blond-Susan🫧, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.